Completed
Intro
Class Central Classrooms beta
YouTube playlists curated by Class Central.
Classroom Contents
Prostate Cancer Genetic Risk Assessment - Webinar - Ambry Genetics
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Disclosures
- 3 Three Inherited Risk Measures
- 4 Genetic Risk Score
- 5 Does GRS Work?
- 6 Broad-sense Validity
- 7 Narrow-sense Validity
- 8 Current Clinical Practice
- 9 Hypothesis for the Need
- 10 Direct Evidence from UKB
- 11 GRS of PCa in UKB
- 12 RPMs of PCa in UKB
- 13 Association with PCa Risk/Mortality
- 14 Simple and Clean Analysis
- 15 PCa Diagnosis-free Survival
- 16 Benefits of Genetic Assessment in
- 17 Predicting Risk: PCa Screening
- 18 Rare Pathogenic Mutations (RPMs)
- 19 Consistent Evidence for HOXB13
- 20 Evidence for Prostate Cancer Susceptibility Genes
- 21 Cumulative Effects of 100 SNPs
- 22 GRS Modifies BRCA2 Effect in PCa
- 23 Predicting Prognosis: Early Stage
- 24 Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate cancer and are Associated with Early Age at Death
- 25 Predicting Therapeutic Responses: Late Stage
- 26 BRCA2 mutations and Response to Carboplatin-based Therapy
- 27 High Levels of Microsatellite instability (MSI-H) and DNA Mismatch Repair Gene (MMR) Mutations: Actionable with Anti-PD-L1 agents
- 28 Conclusions
- 29 Case Example
- 30 Management?
- 31 Surgical Specimen
